Vehicle of TP-03
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Meibomian Gland Dysfunction
Conditions
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
Trial Timeline
Aug 1, 2023 → Jun 15, 2024
NCT ID
NCT06054217About Vehicle of TP-03
Vehicle of TP-03 is a phase 2 stage product being developed by Tarsus Pharmaceuticals for Meibomian Gland Dysfunction. The current trial status is active. This product is registered under clinical trial identifier NCT06054217. Target conditions include Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis.
What happened to similar drugs?
0 of 1 similar drugs in Meibomian Gland Dysfunction were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06054217 | Phase 2 | Active |
Competing Products
3 competing products in Meibomian Gland Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TP-03 + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 2 | 29 |
| SHR8058 eye drops + saline eye drops. | Jiangsu Hengrui Medicine | Phase 3 | 40 |
| Azasite | Merck | Phase 2 | 27 |